other material
confidence high
sentiment positive
materiality 0.65
Immunovant announces positive initial Phase 1 data for IMVT-1402; IgG reduction without albumin or LDL-C changes
Roivant Sciences Ltd.
- SC doses of IMVT-1402 achieved peak IgG reductions similar to batoclimab with no decrease in serum albumin or increase in LDL-C.
- In 300 mg MAD cohort, mean total IgG reduction from baseline was 63% after 4 weekly doses; no albumin drop or LDL-C rise observed.
- All adverse events were mild or moderate; no significant albumin reduction or LDL-C increase at any timepoint (all p>0.05).
- Dosing for 600 mg MAD cohort has recently begun; additional MAD data expected in November 2023.
- IMVT-1402 delivered as simple 2 mL SC injection at 150 mg/mL; SAD data showed potency similar to or greater than batoclimab.